Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1808 results
July 2019
-
Featured NewsNovartis Financial Results – Q2 2019
Novartis announced the company’s financial results for the second quarter and first half of 2019.
-
Media ReleaseNovartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increasedContinuing operations[1] net sales up 8% (cc[2], +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +…
-
Media ReleaseNovartis au 2e trimestre: fortes ventes, croissance à deux chiffres du résultat opérationnel core et lancements de Zolgensma et de Piqray; prévision des ventes et du résultat revue à la hausseChiffre d'affaires net des activités poursuivies[1] en hausse de 8% (tcc[2], +4% USD) soutenu par: Cosentyx: USD 858 millions, +25% (tcc) stimulé principalement par le maintien de la forte…
-
Media ReleaseNovartis erzielt im zweiten Quartal starke Umsätze, eine zweistellige Steigerung des operativen Kernergebnisses und lanciert Zolgensma und Piqray; Anhebung der Umsatz- und GewinnerwartungDer Nettoumsatz der fortzuführenden Geschäftsbereiche[1] steigt aufgrund folgender Beiträge um 8% (kWk[2], +4% USD): Cosentyx erzielt einen Umsatz von USD 858 Millionen (+25% kWk), vor allem dank…
-
Media ReleaseFDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from…
-
Media ReleaseNovartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's preventionAfter review of clinical data from the Generation Program studies, the sponsors concluded that the potential benefit for participants taking CNP520 no longer outweighs the risk Basel, July 11…
-
Flexibility at Novartis: Janneke van der Kamp
Van der Kamp explains how leading by example has encouraged others to adopt flexible working models.
-
Featured NewsGlobal Health & Corporate Responsibility
Novartis transforms its Global Health & Corporate Responsibility organization.
-
Media ReleaseSandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicineSandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1] More than 300,000 European men and women…
-
Media ReleaseNovartis highlights cognition data in secondary progressive multiple sclerosis (SPMS)Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary…
-
Key ReleaseNovartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolioBasel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both…
-
Media ReleaseNovartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapiesData from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures …
Pagination
- ‹ Previous page
- 1
- …
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- …
- 151
- › Next page